opnurasib,jdq443,tislelizumab
novartis,beigene
['kontrast-01', 'jdq443', 'sclc', 'nsclc']
nice figure showing timing and duration of aes from abstract 9007, kontrast-01 study of jdq443 in kras g12c nsclc. would be helpful to see data presented like this in more trials. #asco23 
Thoracic Medical Oncologist @UVACancerCenter | Associate Professor @UvaDOM | Assoc Editor @JCO_ASCO Meeting Abstracts | Husband and father of 2 girls